Paulo Cesar Cotrim

Paulo Cesar Cotrim

Auto-generated profile, based on publicly available information

Paulo Cesar Cotrim

Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
Adriano Cappellazzo CoelhoAdriano Cappellazzo Coelho
Adriano Cappellazzo Coelho
SBStephen Beverley
Stephen Beverley
PCPaulo C Cotrim
Paulo C Cotrim

1 August 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
Adriano Cappellazzo CoelhoAdriano Cappellazzo Coelho
Adriano Cappellazzo Coelho
NMNadine Messier
Nadine Messier
MOMarc Ouellette
Marc Ouellette
PCPaulo C. Cotrim
Paulo C. Cotrim
Pentamidine is a second-line agent in the treatment of leishmaniasis whose mode of action and resistance mechanism are not well understood. In this work, we show that the intracellular ABC protein PRP1 (pentamidine resistance protein 1) (ABCC7) can confer resistance to pentamidine in Leishmania sp. parasites in the intracellular stage.

1 December 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PCPaulo C. Cotrim
Paulo C. Cotrim
LGLynne K. Garrity
Lynne K. Garrity
SBStephen Beverley
Stephen Beverley
We tested a general method for the identification of drug resistance loci in the trypanosomatid protozoan parasiteLeishmania major. Genomic libraries in a multicopy episomal cosmid vector were transfected into susceptible parasites, and drug selections of these transfectant libraries yielded parasites bearing cosmids mediating resistance. Tests with two antifolates led to the recovery of cosmids encoding DHFR-TS or PTR1, two known resistance genes. Overexpression/selection using the toxic nucleoside tubercidin similarly yielded the TOR (toxic nucleoside resistance) locus, as well as a new locus (TUB2) conferring collateral hypersensitivity to allopurinol.Leishmania synthesize ergosterol rather than cholesterol, making this pathway attractive as a chemotherapeutic target. Overexpression/selection using the sterol synthesis inhibitors terbinafine (TBF, targeting squalene epoxidase) and itraconazole (ITZ, targeting lanosterol C14-demethylase) yielded nine new resistance loci. Several conferred resistance to both drugs; several were drug-specific, and two TBF-resistant cosmids induced hypersensitivity to ITZ. One TBF-resistant cosmid encoded squalene synthase (SQS1), which is located upstream of the sites of TBF and ITZ action in the ergosterol biosynthetic pathway. This suggests that resistance to “downstream” inhibitors can be mediated by increased expression of ergosterol biosynthetic intermediates. Our studies establish the feasibility of overexpression/selection in parasites and suggest that many Leishmania drug resistance loci are amenable to identification in this manner.

1 September 2008 in Experimental Parasitology
Verified
Journal Article
Closed access
Adriano Cappellazzo CoelhoAdriano Cappellazzo Coelho
Adriano Cappellazzo Coelho
LGLuciana G. Gentil
Luciana G. Gentil
JSJosé Franco da Silveira
José Franco da Silveira
PCPaulo C. Cotrim
Paulo C. Cotrim

1 April 1995 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
PCPaulo C. Cotrim
Paulo C. Cotrim
GPGlaucia Paranhos-Baccala
Glaucia Paranhos-Baccala
MSMárcia R. Santos
Márcia R. Santos
CMClaudio Mortensen
Claudio Mortensen
MCMARIA ISABEL N. CANO
MARIA ISABEL N. CANO
JFJosé Franco da Silveira Filho
José Franco da Silveira Filho

1 December 2013 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
MSMarcela M. Satow
Marcela M. Satow
EYEdite H. Yamashiro-Kanashiro
Edite H. Yamashiro-Kanashiro
MRMussya C. Rocha
Mussya C. Rocha
LOLuiza K. Oyafuso
Luiza K. Oyafuso
RSRita C. Soler
Rita C. Soler
José Angelo Lauletta LindosoJosé Angelo Lauletta Lindoso
José Angelo Lauletta Lindoso
SUMMARY This study evaluated the applicability of kDNA-PCR as a prospective routine diagnosis method for American tegumentary leishmaniasis (ATL) in patients from the Instituto de Infectologia Emílio Ribas (IIER), a reference center for infectious diseases in São Paulo - SP, Brazil. The kDNA-PCR method detected Leishmania DNA in 87.5% (112/128) of the clinically suspected ATL patients, while the traditional methods demonstrated the following percentages of positivity: 62.8% (49/78) for the Montenegro skin test, 61.8% (47/76) for direct investigation, and 19.3% (22/114) for in vitro culture. The molecular method was able to confirm the disease in samples considered negative or inconclusive by traditional laboratory methods, contributing to the final clinical diagnosis and therapy of ATL in this hospital. Thus, we strongly recommend the inclusion of kDNA-PCR amplification as an alternative diagnostic method for ATL, suggesting a new algorithm routine to be followed to help the diagnosis and treatment of ATL in IIER.